Overview
-

Veritas In Silico Inc.

Veritas In Silico is a biotech company developing novel medicines targeting messenger RNA (mRNA) using its proprietary AI-powered drug discovery platform 'aibVIS', which combines in silico RNA structural analysis with experimental biology. The company operates a platform business model, partnering with major pharmaceutical companies including Shionogi, Toray, and Mitsubishi Gas Chemical to co-develop mRNA-targeting small molecule drugs, while also advancing its own proprietary pipeline focused on nucleic acid medicines for rare diseases. Its innovative drug delivery system 'Perfusio' further strengthens the pipeline by addressing delivery challenges unique to nucleic acid therapeutics.

Market Cap
¥1.95B
US$12.4M
EV
¥0.52B
US$3.29M
Stock¥300▼-5.06%
US$1 = ¥156.80 (2026-10-23)
LTM EV/EBITDA
NM
LTM EV/EBIT
NM
LTM PER
NM
LTM PBR
1.4
x
Stock vs TOPIX (1Y, base=100)vs TOPIX ▼-68.7%pt
1001
Oct 24, 25 – Oct 23, 26StockTOPIX
1Oct 20, 26Achieved 'hit compound acquisition' milestone in joint drug discovery with Toray
MC → EV Bridge
1.95BUS$12.4MMarket Cap0.00BUS$0.00M+ Debt1.43BUS$9.12M− Cash0.00BUS$0.00M− Inv. Sec.0.52BUS$3.29MEV
AI Briefing
Generating insights…
Performance & Balance
Revenue 5Y (¥B)
0.36US$2.30M'23/120.19US$1.24M'24/120.09US$0.58M'25/12
EBITDA 5Y (¥B)
0.06US$0.41M'23/12-0.20-US$1.25M'24/12-0.38-US$2.42M'25/12
Net Income 5Y (¥B)
0.03US$0.21M'23/12-0.24-US$1.51M'24/12-0.43-US$2.71M'25/12
Capital Structure
100%
EquityDebt
Liquidity vs Debt 5Y (¥B)
CashInv. Sec.Debt
1.55US$9.88M'23/122.17US$13.9M'24/121.83US$11.6M'25/12
Shareholders
Top 10 hold 66.6%
1
Shingo NAKAMURA
21.58%
2
Mitsubishi Gas Chemical Company,Inc.
11.27%
3
New Life Science No. 1 Investment Limited Partnership
8.58%
4
MUFG Life Science No. 1 Investment Limited Partnership
7.90%
5
IE Fast & Excellent Investment Limited Partnership
5.11%
6
Masayuki NASHIMOTO
4.60%
7
Genri Co., Ltd.
3.87%
8
Rakuten Securities, Inc.
1.85%
9
Hideki NUNOME
0.92%
10
SBI SECURITIES Co., Ltd.
0.89%
Management
8 officers
Shingo NAKAMURA
Representative Director, President
Oct 2003 Joined Takeda Pharmaceutical Company Limited May 2011 Joined Dow Chemical Japan Limited; Assistant Manager, Sales Department Nov 2011 Joined Catalent Pharma Solutions; General Manager, Business Development Department Jul 2015 Joined Innovation Network Corporation of Japan (INCJ); Strategic Investment Director Nov 2016 Appointed Representative Director of the Company (current)
1972-06-07
Hiroaki HAGIWARA
Director and Executive Officer, General Manager of Administration Department
Jun 2003 Joined Hinoki Holdings Co., Ltd. Apr 2009 General Manager, Accounting Department, Hinoki Holdings Co., Ltd. Feb 2014 Joined VT Holdings Co., Ltd.; concurrently General Manager, Administration Department and General Manager, Business Strategy Department, Nissan Satio Nara Co., Ltd. Oct 2017 Joined ITL Holdings Co., Ltd. Feb 2018 Director in charge of Finance, ITL Holdings Co., Ltd. May 2018 Joined MS Japan Service Co., Ltd.; Executive Officer, General Manager of Administration Department May 2019 Joined the Company; Manager, Finance & Accounting Section, Administration Department Mar 2022 General Manager of Administration Department and Manager of Finance & Accounting Section Mar 2024 Director, General Manager of Administration Department Jan 2025 Director (in charge of Administration Department and Corporate Planning Department) and General Manager of Administration Department Apr 2025 Director and Executive Officer, General Manager of Administration Department (current)
1969-03-11
Isao KODA
Director and Executive Officer, General Manager of Business Development Department
Feb 2003 Joined Nissan Chemical Industries, Ltd. (now Nissan Chemical Corporation); General Manager, Pharmaceutical Division, Nissan Chemical America Corporation Dec 2006 General Manager, Planning & Development Department, Pharmaceutical Business Division, Head Office, Nissan Chemical Corporation Feb 2013 Joined MSD K.K. (Japanese subsidiary of Merck & Co., Inc., U.S.); Director, MRL BD & Licensing Transactions (based at U.S. headquarters) Aug 2017 Joined Apoplus Station Co., Ltd.; General Manager in charge, International Department Dec 2018 Joined the Company; General Manager, Business Development Department Mar 2024 Director, General Manager of Business Development Department, the Company Apr 2025 Director and Executive Officer, General Manager of Business Development Department (current)
1957-05-19
Kinichiro KOMINAMI
Director
Jul 1994 Postdoctoral Researcher, Royal Cancer Research Institute, UK, after obtaining PhD Sep 1998 Research Associate, Medical Institute of Bioregulation, Kyushu University Jun 2001 Joined Nomura Securities Co., Ltd.; seconded to Nomura Research & Advisory Co., Ltd. Aug 2015 Joined Mizuho Securities Co., Ltd.; Director, Corporate Group Sep 2017 Founded Tech & Finance Strategy Co., Ltd.; Representative Director (current) Sep 2017 Outside Director, CellSpect Co., Ltd. (current) Jun 2018 Outside Director, Perseus Proteomics Inc. (current) Jun 2018 Outside Director, Delta-Fly Pharma, Inc. (current) Aug 2019 Outside Director, the Company (current) Aug 2021 Outside Director, E-Gaia Co., Ltd. (current) Dec 2021 Outside Director, Regenerative Medicine iPS Gateway Center Co., Ltd. (now Reprotech Co., Ltd.) (current) Feb 2022 Director, TransMed Co., Ltd. (current) Apr 2022 Founded K International Co., Ltd.; Representative Director (current) Sep 2023 Outside Director, E-Gaia Progress Co., Ltd. (current)
1967-01-20
Minoru HIROOKA
Audit & Supervisory Board Member
Oct 1997 Joined Chuo Audit Corporation May 2001 Registered as Certified Public Accountant Aug 2007 Joined Shin Nihon LLC (now EY ShinNihon LLC) Jan 2009 Opened Hirooka CPA Office; Representative (current) Jan 2009 Outside Audit & Supervisory Board Member, I.O.S. Co., Ltd. (current) Jun 2009 Outside Auditor, Oro Co., Ltd. Mar 2013 Outside Auditor, Agrimedia Co., Ltd. (current) Jan 2015 Founded Hirooka Office Co., Ltd.; Representative Director (current) May 2015 Outside Auditor, Day Dream Co., Ltd. (current) Jun 2016 Outside Auditor, Food Connection Co., Ltd. (current) May 2017 Outside Audit & Supervisory Board Member, the Company (current) Jun 2018 Outside Director (Audit and Supervisory Committee Member), SE Holdings & Incubations Co., Ltd. (current) Mar 2022 Outside Director (Audit and Supervisory Committee Member), Oro Co., Ltd.
1971-07-08
Tomoko SATO
Outside Director
Apr 1977 Joined Nihon Roche K.K. (now Chugai Pharmaceutical Co., Ltd.); Senior Research Scientist, Biological Screening Group, Nihon Roche Research Institute Aug 1985 Received PhD (Science), Ochanomizu University Jul 1998 Joined Bayer Yakuhin, Ltd.; General Manager, Screening Technology Department, Bayer Central Research Institute Jul 2003 General Manager, Business Development & Licensing Division, Bayer Yakuhin, Ltd. Feb 2012 Joined MSD K.K.; Executive Director, Scientific Partnering Jan 2021 President and Representative Director, Schrödinger K.K. Feb 2025 Resigned as President and Representative Director, Schrödinger K.K. May 2025 Founded TMS Drug Discovery Consulting; Representative (current); Advisor to the Company Mar 2026 Outside Director, the Company (current)
1954-12-15
Eiji HAMANO
Full-time Audit & Supervisory Board Member
Apr 1982 Joined TOA Domestic Airlines Co., Ltd. (now Japan Airlines Co., Ltd.) Aug 2008 Joined Japan Airlines International Co., Ltd. (now Japan Airlines Co., Ltd.); Deputy General Manager, Audit Department Jul 2010 Joined Nippon Antenna Co., Ltd.; Internal Audit Office Jul 2012 General Manager, Internal Audit Office, Nippon Antenna Co., Ltd. Jun 2015 Full-time Audit & Supervisory Board Member, Nippon Antenna Co., Ltd. Nov 2025 Resigned as Full-time Audit & Supervisory Board Member, Nippon Antenna Co., Ltd. Mar 2026 Full-time Outside Audit & Supervisory Board Member, the Company (current)
1958-03-22
Minako WAKABAYASHI
Audit & Supervisory Board Member
Apr 1998 Public Prosecutor Apr 2002 Attorney at Law, Atsumi & Sakai (Foreign Law Joint Enterprise) Sep 2004 Attorney at Law, New York Office, Orrick, Herrington & Sutcliffe LLP Sep 2005 Attorney at Law (Partner), Atsumi & Sakai (Foreign Law Joint Enterprise) Sep 2006 Attorney at Law (Global Partner), Tokyo Office, Orrick, Herrington & Sutcliffe LLP / Orrick Tokyo Law Offices (Foreign Law Joint Enterprise) Mar 2022 Outside Audit & Supervisory Board Member, the Company (current) May 2022 Auditor, Japan Wind Power Association (general incorporated association) (current) Sep 2024 Representative Partner (Managing Partner), Tokyo Office, Orrick, Herrington & Sutcliffe LLP / Orrick Tokyo Law Offices (Foreign Law Joint Enterprise) (current)
1972-06-29
Large Shareholding Reports
No filings
Disclosures
No disclosures
Primary Source Filings
EDINET
2026-10-13
Securities Registration Statement
EDINET
2026-08-07
Semi-Annual Securities Report
Period: Jan 2026 – Dec 2026
TDnet
2026-05-11
Q1 Earnings Flash
FY ending Dec 2026
EDINET
2026-03-23
Annual Securities Report
Period: Jan 2025 – Dec 2025
TDnet
2025-11-11
Q3 Earnings Flash
FY ending Dec 2025
EDINET
2025-08-14
Semi-Annual Securities Report
Period: Jan 2025 – Dec 2025
TDnet
2025-05-09
Q1 Earnings Flash
FY ending Dec 2025
EDINET
2025-03-28
Annual Securities Report
Period: Jan 2024 – Dec 2024
EDINET
2024-08-14
Semi-Annual Securities Report
Period: Jan 2024 – Dec 2024
EDINET
2024-05-15
Quarterly Securities Report
Period: Jan 2024 – Mar 2024
EDINET
2024-03-15
Annual Securities Report
Period: Jan 2023 – Dec 2023
TDnet
2024-02-13
Full-Year Earnings Flash
FY ending Dec 2023
EDINETAmended
2024-01-31
Amended Securities Registration Statement
EDINETAmended
2024-01-23
Amended Securities Registration Statement
EDINET
2024-01-05
Securities Registration Statement
Ask AI
I have this company's financials, ownership, and management on hand. Ask me anything from an M&A perspective.
End of Preview

Try the full product

Free demo (no time limit, up to 10 companies). Explore Comps, DCF, LBO, WACC on every screen. Excel export is on the paid plan.

Free Demo (No Time Limit, 10 Companies) →